In­Vi­vo Ther­a­peu­tics shares tank af­ter a third pa­tient death in lead study

Shares of In­Vi­vo Ther­a­peu­tics $NVIV tanked this morn­ing af­ter the Cam­bridge, MA-based biotech said it halt­ed en­roll­ment in its lead IN­SPIRE study af­ter the third pa­tient treat­ed with its spinal cord im­plant died.

In­Vi­vo shares plunged more than 30%.

In­ves­ti­ga­tors de­ter­mined that the death was not trig­gered by their tech­nol­o­gy, which was de­vel­oped out of lab work done by MIT’s Bob Langer and Joseph Va­can­ti. But af­ter a chat with safe­ty mon­i­tors, the biotech says it needs to hit the brakes “to de­ter­mine whether any changes to pa­tient en­roll­ment cri­te­ria re­lat­ed to pa­tients who may have a high­er mor­tal­i­ty risk or oth­er study mod­i­fi­ca­tions are deemed nec­es­sary.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.